Toceranib - CAS 356068-94-5
Catalog number: B0084-455463
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Toceranib (CAS 356068-94-5) is a potent ATP-competitive PDGFR and VEGFR inhibitor (Ki = 5 and 6 nM, respectively); inhibits phosphorylation of c-Kit and suppresses the growth of mast cell lines expressing mutant Kit, inducing cell cycle arrest and apoptosis. Also inhibits FGFR1 (Ki = 0.5 μM). Effective in vivo.
SU 11654; PHA 291639; SU11654; SU-11654; PHA-291639; PHA291639
Canonical SMILES:
1.Retrospective evaluation of toceranib phosphate (Palladia) in cats with oral squamous cell carcinoma.
Wiles V1, Hohenhaus A2, Lamb K3, Zaidi B2, Camps-Palau M2, Leibman N2. J Feline Med Surg. 2016 Jan 11. pii: 1098612X15622237. [Epub ahead of print]
OBJECTIVES: The aim of the study was to determine the clinical benefit and adverse event profile of toceranib phosphate in the treatment of feline oral squamous cell carcinoma (FOSCC).
2.Retrospective evaluation of toceranib phosphate (Palladia®) toxicity in cats.
Merrick CH1, Pierro J2, Schleis SE3, Sones EA4, Wright ZM5, Regan RC6, Siedlecki CT1, Bergman PJ7. Vet Comp Oncol. 2016 Apr 4. doi: 10.1111/vco.12211. [Epub ahead of print]
The purpose of this study was to describe the toxicity profile of toceranib phosphate in tumour bearing cats. Medical records were reviewed from seven institutions. Patients with incomplete medical records and those receiving concurrent chemotherapy or NSAIDs (non-steroidal anti-inflammatory) were excluded. Fifty-five cats met the inclusion criteria. Carcinoma was diagnosed in 55% of cases. Median oral toceranib dose was 2.7 mg kg-1 and was most commonly administered on Monday, Wednesday and Friday. Thrombocytopenia (16.3%) and neutropenia (9.1%) were the most common haematologic toxicities. Azotemia (14.5%) and alanine aminotransferase (ALT) elevations (7.2%) were the most frequently encountered biochemical alterations. Gastrointestinal (GI) toxicity was seen in 21.8% of cats, and was lower than previously reported in dogs. The results of this study showed that treatment of cats with toceranib is well-tolerated and toxicity is uncommon.
3.Phase 1 Dose-Escalation Study with LEC/chTNT-3 and Toceranib Phosphate (Palladia®) in Dogs with Spontaneous Malignancies.
Jang JK1, Chretin J2, Bruyette D2, Hu P1, Epstein AL1. J Cancer Sci Ther. 2015;7(6):167-174. Epub 2015 May 30.
OBJECTIVES: LEC chemokine promotes TH1 responses and recruits immune cells to inflammatory sites. By linking LEC to an antibody targeting tumor necrosis, LEC/chTNT-3 can be used for the immunotherapeutic treatment of tumors. The primary objective of this study was to determine the safety profile of LEC/chTNT-3 and toceranib phosphate (Palladia®) combination therapy in dogs with spontaneous malignancies. Secondary purpose was to determine objective responses to treatment.
4.Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.
Burton JH1,2, Venable RO1,3, Vail DM4, Williams LE5,6, Clifford CA7,8, Axiak-Bechtel SM9, Avery AC10, Thamm DH1. J Vet Intern Med. 2015 Jul-Aug;29(4):1098-104. doi: 10.1111/jvim.13573. Epub 2015 Jun 25.
BACKGROUND: Nonresectable mast cell tumors (MCT) in dogs remain a therapeutic challenge, and investigation of novel combination therapies is warranted. Intermittent administration of tyrosine kinase inhibitors (TKI) combined with cytotoxic chemotherapy may effectively chemosensitize canine MCT while decreasing cost and adverse effects associated with either agent administered as monotherapy.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PDGFR Products

CAS 356068-94-5 Toceranib

(CAS: 356068-94-5)

Toceranib (CAS 356068-94-5) is a potent ATP-competitive PDGFR and VEGFR inhibitor (Ki = 5 and 6 nM, respectively); inhibits phosphorylation of c-Kit and suppres...

CAS 755037-03-7 Regorafenib

(CAS: 755037-03-7)

Regorafenib, also known as BAY 73-4506, is an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds ...

CAS 928037-13-2 Golvatinib

(CAS: 928037-13-2)

golvatinib (also known as E7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial ...

CAS 300842-64-2 NVP-ACC789

(CAS: 300842-64-2)

NVP-ACC789 is a potent, selective and orally active inhibitor of the VEGF receptor tyrosine kinases, antagonizing tumor-driven angiogenesis

CAS 212142-18-2 Vatalanib succinate

Vatalanib succinate
(CAS: 212142-18-2)

Vatalanib succinate is a potent and orally bioactive VEGFR inhibitor (IC50 =37 and 77 nM for VEGFR-2 and -1, respectively) exhibiting potential antineoplastic a...

CAS 38101-59-6 H-Glu-Trp-OH

(CAS: 38101-59-6)

H-Glu-Trp-OH inhibits VEGF, which may inhibit angiogenesis.

CAS 343787-29-1 CP-673451

(CAS: 343787-29-1)

CP-673451 is a selective inhibitor of PDGFRα/β with IC50 of 10 nM/1 nM, exhibits >450-fold selectivity over other angiogenic receptors, has antiangiogenic and a...

ARQ 736 disodium salt
(CAS: 1228237-57-7)

This active molecular is a Proto oncogene protein b raf and Vascular endothelial growth factor A inhibitor originated by ArQule. ARQ 736 is effective in killing...

CAS 284461-73-0 Sorafenib

(CAS: 284461-73-0)

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively.

CAS 926037-48-1 Radotinib

(CAS: 926037-48-1)

Radotinib, also known as IY-5511, is an orally available, hydrochloride salt form of radotinib, a second-generation tyrosine kinase inhibitor of Bcr-Abl fusion ...

CAS 5812-07-7 SU 4312

SU 4312
(CAS: 5812-07-7)

SU 4312 is a potent and selective inhibitor of VEGFR and PDGFR tyrosine kinases (IC50 = 0.8 and 19.4 μM, respectively) wirth selectivity over EGFR and c-Src tyr...

CAS 1140909-48-3 Cabozantinib malate (XL184)

Cabozantinib malate (XL184)
(CAS: 1140909-48-3)

Cabozantinib malate is the malate of Cabozantinib, a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL w...

CAS 728033-96-3 OSI-930

(CAS: 728033-96-3)

OSI-930 is a selective thiophene-derived tyrosine kinase inhibitor with potential antineoplastic activity. Tyrosine kinase inhibitor OSI-930 inhibits stem cell ...

CAS 252916-29-3 Orantinib

(CAS: 252916-29-3)

TSU-68 (SU6668; Orantinib) is a novel multiple receptor tyrosine kinase inhibitor with IC50 of 2.1 μM, 8 nM and 1.2 μM for VEGF-R1, PDGF-Rβ and FGF-R1, respecti...

CAS 326914-10-7 SU11652

(CAS: 326914-10-7)

SU11652 is a cell-permeable and sunitinib-like inhibitor of tyrosine kinase receptor (RTK) and angiogenesis with antineoplastic property. It selectively inhibit...

CAS 627908-92-3 SU14813

(CAS: 627908-92-3)

SU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor...

CAS 886563-25-3 ZK-261991

(CAS: 886563-25-3)

ZK-261991 is an orally active VEGFR tyrosine kinase inhibitor with an IC50 of 5 nM for VEGFR2. The high efficacy, including tumour regression in established tum...

CAS 475207-59-1 Sorafenib Tosylate

Sorafenib Tosylate
(CAS: 475207-59-1)

Sorafenib Tosylate (Bay 43-9006) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively.

CAS 1005780-62-0 TAK-593

(CAS: 1005780-62-0)

TAK-593 is an oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and pl...

CAS 635702-64-6 Pazopanib HCl

Pazopanib HCl
(CAS: 635702-64-6)

Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 1...

Chemical Structure

CAS 356068-94-5 Toceranib

Quick Inquiry

Verification code

Featured Items